| 000 | 01851 a2200493 4500 | ||
|---|---|---|---|
| 005 | 20250514230134.0 | ||
| 264 | 0 | _c20060919 | |
| 008 | 200609s 0 0 eng d | ||
| 022 | _a0049-3848 | ||
| 024 | 7 |
_a10.1016/j.thromres.2005.04.011 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aLubenow, Norbert | |
| 245 | 0 | 0 |
_aResults of a systematic evaluation of treatment outcomes for heparin-induced thrombocytopenia in patients receiving danaparoid, ancrod, and/or coumarin explain the rapid shift in clinical practice during the 1990s. _h[electronic resource] |
| 260 |
_bThrombosis research _c2006 |
||
| 300 |
_a507-15 p. _bdigital |
||
| 500 | _aPublication Type: Comparative Study; Journal Article; Research Support, Non-U.S. Gov't | ||
| 650 | 0 | 4 | _aAged |
| 650 | 0 | 4 |
_aAncrod _xadministration & dosage |
| 650 | 0 | 4 | _aCanada |
| 650 | 0 | 4 |
_aChondroitin Sulfates _xadministration & dosage |
| 650 | 0 | 4 | _aCohort Studies |
| 650 | 0 | 4 |
_aCoumarins _xadministration & dosage |
| 650 | 0 | 4 |
_aDermatan Sulfate _xadministration & dosage |
| 650 | 0 | 4 | _aFemale |
| 650 | 0 | 4 | _aGermany |
| 650 | 0 | 4 |
_aHeparin _xadverse effects |
| 650 | 0 | 4 |
_aHeparitin Sulfate _xadministration & dosage |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 | _aMale |
| 650 | 0 | 4 | _aOutcome Assessment, Health Care |
| 650 | 0 | 4 | _aPlatelet Count |
| 650 | 0 | 4 |
_aPractice Patterns, Physicians' _xtrends |
| 650 | 0 | 4 | _aRetrospective Studies |
| 650 | 0 | 4 | _aSurvival Analysis |
| 650 | 0 | 4 |
_aThrombocytopenia _xchemically induced |
| 700 | 1 | _aWarkentin, Theodore E | |
| 700 | 1 | _aGreinacher, Andreas | |
| 700 | 1 | _aWessel, Antje | |
| 700 | 1 | _aSloane, Debi-Ann | |
| 700 | 1 | _aKrahn, Erica L | |
| 700 | 1 | _aMagnani, Harry N | |
| 773 | 0 |
_tThrombosis research _gvol. 117 _gno. 5 _gp. 507-15 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1016/j.thromres.2005.04.011 _zAvailable from publisher's website |
| 999 |
_c15569928 _d15569928 |
||